Kroger's shares rise as grocer says shoppers seek lower prices, cook more at home - CNBC

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors – PR Newswire

August 1, 2025

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors PR Newswire
European Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia Docwire News
Novo Nordisk (NVO) Gains Positive CHMP Nod for Alhemo Label Expa GuruFocus
Novo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B Insider Monkey
FDA approves concizumab-mtci for hemophilia A/B without inhibitors in patients 12 years and older Contemporary Pediatrics